The recruitment is targeted in the field of Basic and Preclinical Neuroscience. The successful candidate will hold a full-time research position or clinical researcher. This person will develop a research program on neuroscience funded by external research organizations. Special attention will be given to research programs focusing on the study of opioid neuropharmacology. Research programs related to other fields of neuroscience will also be considered. The candidate will supervise graduate students enrolled in master's and doctoral programs in neuroscience, pharmaceutical sciences, molecular medicine or science and engineering.
Interested candidates must hold a PhD, a PharmD or a MD degree and have completed a postdoctoral training in neuroscience or other relevant discipline. He/She must exhibit excellent research skills, as demonstrated by success in obtaining publication of articles in peer-reviewed journals. Candidates must be able to teach in French and work in a multidisciplinary team.
Expected date to start: by 13 January 2020 at the latest.
The Neuroscience Axis is committed to principles of equity, diversity and inclusion (EDI) and invites all qualified individuals to apply, particularly women, members of visible minorities/racialized groups, Indigenous Peoples and persons with disabilities. Priority will be given to those with Canadian citizenship or permanent resident status.
Submit by email a letter of interest, a curriculum vitae, a reference letter and summary of teaching and research interests before August 1, 2019, to the Neuroscience Axis Scientific Coordinator.
Internal Number: 2019-063
About Neuroscience Axis at Centre de recherche du CHU de Québec - Université Laval
The Centre de recherche du CHU (CRCHU) de Québec – Université Laval is one of the largest hospital-based research centers in Canada. It brings together more than 500 regular researchers, associates, affiliates and honorary members grouped in 7 axes of fundamental and / or clinical research. The Neuroscience Axis is made up of 55 researchers, 30 of whom are basic researchers and 25 are clinicians. The core strengths of the Axis include neuroimmunology, neurodegenerative diseases and neurotrauma.